Fycompa Articles

Eisai's Fycompa shows clear therapeutic benefit in hard-to-treat epilepsy

10 May 2013

Eisai joins trend to enter Russian pharma market, with Halaven launch

26 March 2013

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

8 March 2013

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30 January 2013

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19 December 2012

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11 December 2012

FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR

23 October 2012

Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst

13 September 2012

Positive final pivotal Ph III results for Eisai's Fycompa

21 August 2012

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30 July 2012

Eisai's Fycompa improves seizure control, pivotal Ph III study shows

27 July 2012

Zonegran Russian approval prompts Eisai's expansion in that market

28 June 2012

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27 May 2012

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end